Auron Therapeutics

Private

Newton, MassachusettsHealthcare & Life Scienceshttps://www.aurontx.com/

Last Round

Series B

Feb 4, 2025

Est. Valuation

$158M

Total Funding Raised

$87.75M

Company Overview

Auron Therapeutics is a biotechnology company that develops targeted small molecule therapies by analyzing dysfunctional cell states to treat cancers and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoveryoncologydifferentiation therapysmall-molecule therapycell-state plasticityprotein degraderAI drug discoveryprecision medicinemulti-omic datasetsbiomarker identificationin silico drug discoverycomputational biologyclinical-stage biotechtargeted therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Auron Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Auron Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Auron Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Feb 4, 2025
Series A	Jul 20, 2022
Seed	Jan 27, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Glenn Goddard

Chief Financial Officer

Executive Team

Auron Therapeutics Investors

Notable investors and investment history

Auron Therapeutics investors
Investor	Rounds
Apollo Ventures	Series B, Series A
DCVC Bio	Series B, Series A
BrightEdge	Series B, Series A, Seed
BrightEdge	Series B, Series A, Seed
Arkin Holdings	Series B, Series A
Mubadala Capital	Series B, Series A
Qiming	Series B, Series A, Seed

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Oct 13, 2025
Will attend the 8th Annual Targeted Protein Degradation & Induced Proximity Summit.
Apr 3, 2025
Presented data at the Small Cell Lung Cancer Meeting in New York.

View all signals

Auron Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Auron Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Auron Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewton, Massachusetts

Employee Range24

Year Founded2018

Last FundingFeb 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.